Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific

Obesity Clinical Trial

— ACTION-APAC  

Official title:

Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05250427
• Other study ID #: DAS-006
• Secondary ID: U1111-1266-5484
• Status: Completed
• Start date: April 26, 2022
• Est. completion date: May 23, 2022

Study information

• Verified date: June 2022
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor through existing databases/panels in APAC region.

The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12404
• Est. completion date: May 23, 2022
• Est. primary completion date: May 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

People Living with Obesity

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

2. Male or female, aged above or equal to 18 years at the time of signing informed consent

3. Lives in one of the target countries

4. Current BMI of at least 25 kg/m^2 for all countries (except Singapore which has current BMI 27 kg/m^2) based on self-reported height and weight

Health Care Professionals

1. Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)

2. Male or female, aged greater than or equal to 18 years at the time of signing informed consent.

3. Physician

4. Primary Care Providers (PCPs) whose specialty is Family practice, General practice, Internal Medicine

5. Non-PCP Specialties whose specialty is Endocrinologist, Cardiologist, Gastroenterologist, Obstetrics/Gynaecologist, Bariatrics/Obesity Medicine, Nutrition Specialist (physician) Orthopaedist, Aesthetics Medicine

6. Specialty is not surgeon (including bariatric or plastic surgeon)

7. Practices in the target countries

8. In clinical practice for at least 2 years

9. Spends at least 50% time in direct patient care

10. Has seen at least 100 patients in past month

11. Has seen at least 10 patients in past month who have obesity defined as: a patient with a BMI greater than or equal to 25 kg/m^2 for all countries (except Singapore which has current greater than or equal to BMI 27 kg/m^2) with or without comorbidities.

Exclusion criteria:

People Living with obesity

1. Previous participation in this study. Participation is defined as having given online consent in this study

2. Currently pregnant

3. Participates in intense fitness or body building programs

4. Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months

5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Health Care Providers

1. Previous participation in this study. Participation is defined as having given informed consent in this study.

2. Unwillingness, inability, or language barriers precluding adequate understanding or cooperation

Related Conditions & MeSH terms

• Obesity

Intervention

Other:
• No treatment given
No treatment given

Locations

Country	Name	City	State
Bangladesh	Novo Nordisk Investigational Site	Dhaka
India	Novo Nordisk Investigational Site	Bangalore
Indonesia	Novo Nordisk Investigational Site	Jakarta
Malaysia	Novo Nordisk Investigational Site	Kuala Lumpur
Pakistan	Novo Nordisk Investigational Site	Karachi
Philippines	Novo Nordisk Investigational Site	Manila
Singapore	Novo Nordisk Investigational Site	Singapore
Thailand	Novo Nordisk Investigational Site	Bangkok
Vietnam	Novo Nordisk Investigational Site	Ho Chi Minh

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Bangladesh,  India,  Indonesia,  Malaysia,  Pakistan,  Philippines,  Singapore,  Thailand,  Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight loss motivators for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Primary	Weight loss barriers for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Primary	Weight loss management for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Primary	Weight loss responsibility for improving health of PLwO	Multi-select from defined list	At the time of survey response (Day 1)
Primary	Proportion of PLwO who made serious weight loss effort	Number of weight loss efforts; percentage of patients	At the time of survey response (Day 1)
Primary	Response to weight loss discussions	Single select from defined list	At the time of survey response (Day 1)
Primary	Attitudes towards obesity and weight management and Interactions of PLwOs with HCPs	5-point Likert scales	At the time of survey response (Day 1)